Weight: ___________ kg Height: ___________ cm

Allergies: 

Diagnosis Code: 

Treatment Start Date: ________________ Patient to follow up with provider on date: ________________

**This plan will expire after 365 days at which time a new order will need to be placed**

GUIDELINES FOR ORDERING

1. Send FACE SHEET and H&P or most recent chart note.
2. Hepatitis B (Hep B surface antigen and core antibody total) screening must be completed prior to initiation of treatment and the patient should not be infected. Please send results with order.
3. If patient is at high risk for TB exposure, a Tuberculin test must have been placed and read as negative prior to initiation of treatment (PPD or QuantiFERON Gold blood test). If result is indeterminate, a follow up chest X-ray must be performed to rule out TB. Please send results with order.
4. Patient should have regular monitoring for hepatitis B, infection, and renal dysfunction.

PRE-SCREENING: (Results must be available prior to initiation of therapy):

- Hepatitis B surface antigen and core antibody total test results scanned with orders.
- Tuberculin skin test or QuantiFERON Gold blood test results scanned with orders if patient is at high risk for TB exposure.
- Chest X-Ray result scanned with orders if TB test result is indeterminate.
- TB screening is not necessary. Patient is not at high risk for TB exposure.

LABS:

- CBC with differential, Routine, ONCE, every (visit)(days)(weeks)(months) – Circle One
- Liver Set (AST, ALT, BILI TOTAL, BILI DIRECT, ALK PHOS, ALB, PROT TOTAL), Routine, ONCE, every (visit)(days)(weeks)(months) – Circle One
- IGG, SERUM, Routine, ONCE, every (visit)(days)(weeks)(months) – Circle One

NURSING ORDERS:

1. TREATMENT PARAMETER – Hold treatment and contact provider if Hepatitis B surface antigen or core antibody total test result is positive, TB test result is positive, or if screening has not been performed.
2. First infusion or prior infusion reactions: infuse riTUXimab-abbs via pump (no additional filter is required) slowly at 50 mg/hr for the first hour. If no infusion related reactions are seen, increase rate gradually by 50 mg/hr every 30 minutes to a maximum of 400 mg/hr.
3. Subsequent infusions if no infusion reactions: infuse riTUXimab-abbs via pump at 100 mg/hr for the first hour. If no infusion related reactions are seen, increase rate gradually by 100 mg/hour every 30 minutes to a maximum of 400 mg/hour as tolerated.
4. NURSING COMMUNICATION – HYPERSENSITIVITY/INFUSION REACTION #1 -- Monitor patient for riTUXimab-abbs infusion related reactions for 1 hour (first infusion) or 30 minutes (second infusion) after completion of riTUXimab-abbs infusion. Monitoring not required for third infusion and beyond, if no
previous infusion reactions. Lengthened monitoring recommended for previous infusion reactions, contact provider for guidance.

5. VITAL SIGNS -- First infusion: During riTUXimab-abbs infusion obtain vital signs at baseline, then every 15 minutes for the first hour, then every 30 minutes with rate escalation, then every hour for the duration of the infusion.

6. VITAL SIGNS -- Subsequent infusions: During riTUXimab-abbs infusion obtain vital signs at baseline, then every 30 minutes with rate escalation, then every hour for the duration of the infusion.

7. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes

PRE-MEDICATIONS: (Administer 30 minutes prior to infusion)

1. acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit
2. diphenhydramine (BENADRYL) capsule, 50 mg, oral, ONCE, every visit. Give either loratadine or diphenhydramine, not both.
3. loratadine (CLARITIN) tablet, 10 mg, oral, ONCE AS NEEDED if diphenhydramine is not given, every visit. Give either loratadine or diphenhydramine, not both.
4. methylprednisolone sodium succinate (SOLU-MEDROL), 125 mg, intravenous, ONCE, every visit

MEDICATIONS:
(If insurance requires a different biosimilar agent, pharmacy will update the order per OHSU CDTM)

- riTUXimab-abbs (TRUXIMA) 1000 mg in sodium chloride 0.9%, intravenous, ONCE, Infuse per nursing order.

Interval: (must check one)
- Once
- Initial Dosing: Every 2 weeks x 2 doses
- Maintenance Dosing: Once every 26 weeks (6 months) after treatment initiation
- Every _____ weeks x _____ doses
HYPERSENSITIVITY MEDICATIONS:

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.

2. diphenhydramINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x1 dose for hypersensitivity or infusion reaction

3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity or infusion reaction

4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x1 dose for hypersensitivity or infusion reaction

5. famotidine (PEPCID) 20 mg, intravenous, AS NEEDED x1 dose, for hypersensitivity or infusion reaction

6. acetaminophen (TYLENOL) tablet, 650 mg, oral, EVERY 4 HOURS AS NEEDED for infusion related fever

7. meperidine (DEMEROL) injection, 25-50 mg, intravenous, EVERY 2 HOURS AS NEEDED for infusion-related severe rigors in the absence of hypotension, not to exceed 50 mg/hr

8. sodium chloride 0.9% solution, 1000 mL, intravenous, AS NEEDED, Infuse at 200 mL/hr when infusion is stopped for emergency or PRN medications

By signing below, I represent the following:
I am responsible for the care of the patient (who is identified at the top of this form);
I hold an active, unrestricted license to practice medicine in: □ Oregon □ __________________________ (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);
My physician license Number is # __________________________ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: __________________________ Date/Time: __________________________
Printed Name: __________________________ Phone: __________________________ Fax: __________________________
OLC Central Intake Nurse:
Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient’s preferred clinic location:

☐ Beaverton
   OHSU Knight Cancer Institute
   15700 SW Greystone Court
   Beaverton, OR 97006
   Phone number: 971-262-9000
   Fax number: 503-346-8058

☐ NW Portland
   Legacy Good Samaritan campus
   Medical Office Building 3, Suite 150
   1130 NW 22nd Ave.
   Portland, OR 97210
   Phone number: 971-262-9600
   Fax number: 503-346-8058

☐ Gresham
   Legacy Mount Hood campus
   Medical Office Building 3, Suite 140
   24988 SE Stark
   Gresham, OR 97030
   Phone number: 971-262-9500
   Fax number: 503-346-8058

☐ Tualatin
   Legacy Meridian Park campus
   Medical Office Building 2, Suite 140
   19260 SW 65th Ave.
   Tualatin, OR 97062
   Phone number: 971-262-9700
   Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders